Radioisotope couple for tumour diagnosis and therapy

Pinterest LinkedIn Tumblr +

Researchers have reported in the journal ACS Omega a promising combination of radioisotope-carrying molecules for use in radiotheranostics – a diagnosis-and-treatment approach based on the combination of medical imaging and internal radiation therapy with radioactive elements.

Radioisotopes – atoms displaying radioactivity can be used for both diagnosing and treating cancer.

For diagnosis, radioisotopes that emit gamma rays are used because of their penetrating capability, while for treatment, isotopes emitting alpha particles, beta particles, or similar cytotoxic radiation are needed.

In recent years, an approach combining therapy and diagnosis both based on radioisotopes, called ‘radiotheranostics’, has gained significance.

The key idea is that both the diagnostic and the therapeutic isotope can be brought to a tumour by attaching it to the same carrier molecule.

Now, Kazuma Ogawa from Kanazawa University and colleagues have synthesised a radiotheranostic system with astatine (At-211) as the alpha-particle emitter and iodine (I-123) as the gamma-radiation source.

A few types of molecules can be used as radioisotope carriers.

Ogawa and colleagues were able to use a peptide (a biomolecule consisting of a chain of amino acids) as the carrier for both the astatine and the iodine isotope.

Specifically, they worked with a peptide containing the so-called RGD sequence of amino acids.

The RGD motif plays an important role in cell membrane binding; its cell-adhesive activity makes it a good component for designing molecules for targeting tumours.

The theranostic carrier molecules were synthesised through a series of chemical reactions, the last step being a halogenation – the replacement of a particular molecular component by a halogen – both astatine and iodine are halogens, having similar chemical properties.

After the successful synthesis of the At-211 and I-125 carrier molecules, the researchers tested their behaviour in vivo.

They simultaneously injected the two compounds in tumour-bearing mice, and looked at the biodistribution of the radioactive isotopes – that is, in which parts of the body they occur, and how abundantly.

The main finding was that the At-211- and I-125-labeled RGD peptides displayed biodistributions that were very similar, with a high accumulation in the tumour – a prerequisite for operating as a theranostic system.

Another iodine isotope, I-123, is foreseen to be the diagnostic radioisotope, but I-125 has a much longer half-life, making it easier to work with in the present experiments.

The work of Ogawa and colleagues is an important step forward in the development of radiotheranostics.

Quoting the scientists: “This method could be applicable to other peptides directly targeted to cancer.  Moreover, future efforts should be focused on application of other radiohalogens … as positron emitters for PET [positron–electron tomography] imaging …”


Radioactive atoms (radioisotopes) decay into other atoms, thereby emitting radiation.

Different types of radiation occur, including alpha particle (helium nucleus) emission, and gamma ray (highly energetic electromagnetic radiation) emission.

The former can be used for treatment – alpha particles can destroy cancer cells – while the latter can be used for imaging.

The goal of combining both diagnosis and treatment in one approach based on radioisotopes has led to the concept of ‘radiotheranostics’.

The key property of a radiotheranostic system is that both radioisotopes target the same area in the body, a tumour in the case of cancer – their biodistribution has to be the same.

Kazuma Ogawa from Kazanawa University and colleagues have now developed a radiotheranostic system, with an astatine isotope as the alpha-particle source and an iodine isotope as the gamma-ray source.

Importantly, both atoms are halogens; because they belong to the same group in the periodic table, they have similar chemical properties.

Because of this chemical similarity, the scientists could use the same carrier molecule for both isotopes (the carrier molecule delivers the radioisotope to the targeted body part).

Source: Kanazawa University


About Author

ONA Editor

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.